XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Industry Segment and Geographic Area Information (Tables)
 12 Months Ended
Jan. 02, 2022
Segment Reporting [Abstract]  
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations
Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended:
 
January 2,
2022		January 3,
2021		December 29,
2019
 (In thousands)
Discovery & Analytical Solutions
Product revenue$1,358,484 $995,216 $1,054,862 
Service revenue776,746 720,587 691,299 
Total revenue2,135,230 1,715,803 1,746,161 
Operating income from continuing operations(1)
189,798 183,471 238,331 
Diagnostics
Product revenue1,970,618 1,783,509 962,180 
Service revenue961,321 283,433 175,332 
Total revenue2,931,939 2,066,942 1,137,512 
Operating income from continuing operations(1)(2)
1,219,944 874,206 189,330 
Corporate
Operating loss from continuing operations(3)
(77,364)(79,096)(65,688)
Continuing Operations
Product revenue3,329,102 2,778,725 2,017,042 
Service revenue1,738,067 1,004,020 866,631 
Total revenue5,067,169 3,782,745 2,883,673 
Operating income from continuing operations1,332,378 978,581 361,973 
Interest and other expense, net52,492 72,217 124,831 
Income from continuing operations before income taxes$1,279,886 $906,364 $237,142 
____________________________
(1)Legal costs for significant litigation matters and settlements in the Company's Discovery & Analytical Solutions segment were $5.9 million and $2.2 million for fiscal years 2020 and 2019, respectively. Legal costs for significant litigation matters and settlements in the Company's Diagnostics segment were $0.1 million, $1.2 million and $0.1 million for fiscal years 2021, 2020 and 2019, respectively.
(2)Asset impairment in the Company's Diagnostics segment was $3.9 million and $7.9 million for fiscal years 2021 and 2020.
(3)Costs for significant environmental matters were $5.2 million for fiscal year 2020. Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019.
Schedule of Depreciation, Amortization and Capital Expenditures
Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 2, 2022:
 Depreciation and Amortization ExpenseCapital Expenditures
 January 2,
2022		January 3,
2021		December 29,
2019		January 2,
2022		January 3,
2021		December 29,
2019
 (In thousands)(In thousands)
Discovery & Analytical Solutions$141,261 $93,516 $74,445 $41,686 $20,217 $27,778 
Diagnostics214,178 149,738 136,476 57,206 55,236 46,863 
Corporate2,565 3,253 3,104 996 2,053 1,690 
Continuing operations$358,004 $246,507 $214,025 $99,888 $77,506 $76,331 
Schedule of Total Assets by Segment
 Total Assets
 January 2,
2022		January 3,
2021		December 29,
2019
 (In thousands)
Discovery & Analytical Solutions$10,177,834 $3,600,860 $3,082,917 
Diagnostics4,692,816 4,228,943 3,368,598 
Corporate129,904 130,512 87,049 
Total assets$15,000,554 $7,960,315 $6,538,564 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 2, 2022 and net long-lived assets based on physical location as of January 2, 2022 and January 3, 2021:
 Revenue
 January 2,
2022		January 3,
2021		December 29,
2019
 (In thousands)
U.S.$2,046,914 $1,269,293 $974,187 
International:
China670,084 492,283 581,688 
United Kingdom417,199 362,591 70,703 
Other international1,932,972 1,658,578 1,257,095 
Total international3,020,255 2,513,452 1,909,486 
Total sales$5,067,169 $3,782,745 $2,883,673 
 
 
Net Long-Lived Assets(1)
 January 2,
2022		January 3,
2021
 (In thousands)
U.S.$343,723 $197,755 
International:
Germany148,048 149,105 
China79,851 75,199 
Other international256,956 229,099 
Total international484,855 453,403 
Total net long-lived assets$828,578 $651,158